Moderna and Merck announce an investigational individualized neoantigen therapy
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Affordability is key to providing accessible healthcare for Bharat.
The new team members, Solenn Percelay and Noémie Spinelli, will support the organization’s commitment to excellence in humanized mouse model care and use
Enabling wireless monitoring In ambulances and homes
ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
Venkat Nageswar Chalasani has been appointed as an Independent Director of Apitoria Pharma with effect from April 4, 2023
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
Subscribe To Our Newsletter & Stay Updated